Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Medigene AG
In an interview with Scrip, CEO Saurabh Saha elaborates on the first-of-its-kind R&D model.
Executives share their expectations and hopes around the multi-faceted topic of patient access to medicines. From health inequities to value assessment and reimbursement trends, expectations for change abound.
Report released as soon-to-be committee chair Ron Wyden, D-OR, assembles plans for drug pricing legislation in the new Democratic-controlled Senate.
The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.
- Gene Therapy, Cell Therapy
- Large Molecule
Drug Discovery Tools
- Molecular Diversity
- Other Names / Subsidiaries
- Trianta Immunotherapies GmbH
- Medigene Immunotherapies GmbH